医薬品セクターWeekly 5月11-15日: 2026年1-3月の決算終了、最も印象の良い銘柄は大塚HD

Research evidence excerpt

医薬品セクターWeekly 5月11-15日: 2026年1-3月の決算終了、最も印象の良い銘柄は大塚HD

ost hoc analysis of ARCHES.

First data disclosure from the first-in-human phase 1/2 trial of SMP-3124LP, the first investigational pegylated

May 30 13:30 - 16:30 May 31 3:30 - 6:30 Sumitomo Pharma SMP-3124 Poster 3081

liposome CHK1 inhibitor, in patients with selected advanced solid tumors.

ONO-4578 combined with nivolumab (NIVO) and chemotherapy (chemo) as first-line (1L) treatment for patients

Oral Abstract

Jun 1 11:53 - 12:05 Jun 2 1:53 - 2:05 Ono Pharmaceutical ONO-4578 4007 with HER2-negative unresectable advanced or recurrent (adv/rec) gastric/gastroesophageal junction cancer

Session

(G/GEJ): A randomized, double-blind, phase 2 trial (ONO-4578-08).

Oral Abstract Nivolumab plus ipilimumab combined with chemotherapy as first-line treatment for HER2-negative unresectable

Jun 1 11:41 - 11:53 Jun 2 1:41 - 1:53 Ono Pharmaceutical Opdivo 4006

Session advanced or recurrent gastric/gastroesophageal junction cancer: a randomized phase 3 trial (ATTRACTION-6)

First-line (1L) trastuzumab deruxtecan (T-DXd)–based regimens in advanced HER2-expressing gastric cancer

May 30 9:00 - 12:00 May 30 23:00 - 2:00 Daiichi Sankyo Enhertu Poster 4022 (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): Safety results

from DESTINY-Gastric03 (DG-03) Part 2 arms D and F, and Part 4.

Clinical Science Trastuzumab deruxtecan (T-DXd) + durvalumab (D) in patients (pts) with previously untreated HER2+

May 31 9:18 - 9:30 May 31 23:18 - 23:30 Daiichi Sankyo Enhertu 1012

Symposium unresectable/metastatic breast cancer (mBC): Final analysis from DESTINY-Breast07.

Rapid Oral A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab